Jeromie Ballreich (@jeromie_b) header
Jeromie Ballreich (@jeromie_b) profile picture

Associate Research Prof at Johns Hopkins Uni. PhD in Health Economics and Policy. Interests in policy, econ, drug pricing. Avid wheelchair user.

Baltimore, MD
Joined January 2016
Photo by Jeromie Ballreich (@jeromie_b)Photo by Jeromie Ballreich (@jeromie_b)Photo by Jeromie Ballreich (@jeromie_b)Photo by Jeromie Ballreich (@jeromie_b)Photo by Jeromie Ballreich (@jeromie_b)Photo by Jeromie Ballreich (@jeromie_b)Photo by Jeromie Ballreich (@jeromie_b)Photo by Jeromie Ballreich (@jeromie_b)Photo by Jeromie Ballreich (@jeromie_b)Photo by Jeromie Ballreich (@jeromie_b)
Jeromie Ballreich retweeted
I am the payments logistics officer at the United States Treasury Department who has personally touched every version of the free money this country has been promised since 2020, and I am the only person left in this building who remembers how the first one actually went, because the first one is the only one that was ever real. Spring 2020. Economic Impact Payments, $1,200 a person, funded, appropriated, moving. Then Mnuchin's office ordered the president's name onto the memo line. Not a rubber stamp. A printed signature, the first time a president's name had ever gone on an IRS payment. Commissioner Rettig wasn't told until the request was already in motion. Our engineers had to reprogram the check-printing software and run it through testing before a single check could clear, because the system had never been built to hold a name that wasn't the Treasurer's. 70 million people waited an extra few days for their own emergency relief, during a pandemic, so a signature could finish QA. I sat in the room where someone asked if we could just skip the testing and was told no, we are not shipping the president's name with a rendering bug in it. The actual money moved slower so the branding could move faster. Every version since has been the branding moving faster and the money not moving at all. Version one was the DOGE Dividend. It didn't come from this building. It came from a 30-year-old hedge fund manager named James Fishback, CEO of a firm called Azoria, who has said publicly that the number arrived to him in a dream. He posted it to Musk in February of 2025: take 20% of whatever DOGE saves and cut it into checks, math it out to roughly $5,000 a household if the savings hit $2 trillion. Musk replied that he'd check with the president. The president checked. Within days it was a line in a press briefing, no legislation, no appropriation, just a number that had been asleep in one man's head 12 hours earlier now sitting on the Resolute desk. By May, DOGE's own public savings tracker read $175 billion, not $2 trillion, which works out to $1,086.96 per taxpayer, not $5,000. Nobody issued a correction. The number just stopped being said out loud. And when Fishback later described himself as having advised DOGE, a former senior DOGE adviser went on the record to say, quote, you didn't advise DOGE. So the origin story of the $5,000 figure still being used today, 18 months and 2 rebrands later, is a dream, a tweet, and a denial. I have that DOGE savings tracker bookmarked. I check it the way other people check their portfolio. Version two was the Tariff Dividend, announced that November. $2,000 a person this time, lower number, new funding source: tariff revenue instead of imaginary government savings. This one at least had a real number behind it: $195 billion collected in tariffs for the fiscal year. Economists ran the arithmetic before we did. Cato called it fiscal fantasy in print. A deputy chief economist at Oxford Economics warned that stacking a stimulus check on top of the existing tax cuts could overheat the economy. The math didn't work even before the legal problem showed up, and then the legal problem showed up: the Supreme Court struck down the IEEPA tariffs in February, the ones the dividend was supposed to be funded from, and by May we were issuing refunds to importers faster than customs was collecting anything. I watched the ledger cross from positive to negative in the same spreadsheet tab we'd built to track the dividend. We didn't rename the tab. We just stopped opening it. Version three is the Trump Dividend, the one I'm actually being asked to price this week. Same number as version one, $5,000, announced Tuesday night from the stage of the midterm convention. Quote: if the Republicans win the House of Representatives and the United States Senate, both of them, because of our tremendous economic success, I will issue a dividend to every adult citizen in the United States for $5,000. One condition attached, and it isn't a funding mechanism, it's a spending restriction: the money has to stay in the country, no Canada, no China, no Germany, his words. So the government has now, for the first time in three attempts, specified where the imaginary money is allowed to be imaginarily spent. Commentators started using the word bribe before the applause even finished. There's a real federal statute for this: 18 U.S.C. 597, expenditures to influence voting, a fine or up to 2 years if it's willful. Nobody in this building has said the statute's number out loud in a meeting, and I've listened for it, because there's a comfortable legal argument sitting right there in plain sight: you cannot criminally buy a vote with money that was never appropriated, never budgeted, and has no line item anywhere in the federal government. It isn't a bribe. A bribe requires a bribe. I priced it anyway, because pricing a number has never once required the number to exist. 270 million adults, $5,000 each, $1.35 trillion, against a national debt that closed this week at $40.1 trillion. It costs 7 times what version two's tariffs brought in at their peak. I put the number in the deck. I did not put in a funding source, because there's a blank cell where that used to go, and I've started to think of that blank cell as the actual through-line of my career here. Four checks. One real. One dreamed by a guy who isn't even employed by the government he says he advised. One that went negative by court order. One that costs a Senate seat instead of a tax dollar. And I'm still on the invite list for the pricing meeting, because I'm the only one left who was in the room in 2020 when we tested a signature before we tested the money.
.@POTUS announces the TRUMP DIVIDEND: If Republicans win both the House and the Senate, because of our tremendous economic success, I will issue a dividend to every adult citizen in the United States for $5,000
Readers added context they thought people might want to know
The President of the United States has no constitutional or statutory authority to issue a dividend check on behalf of the US Government. Only the Congress can authorize and appropriate these funds. constitutioncenter.org/the-constituti…
Readers added context they thought people might want to know
This post is satire. Peter Girnus's X profile is self-desribed as a "cyber populist" and "hacker/writer." He has no know affiliation to federal work or involvement with stimulus-type checks for Americans. Further, his work history shows only non-federal cybersecurity work. linkedin.com/in/peter-girnu…
200
1,465
151
8,163
2,955,813
Jeromie Ballreich retweeted
Thank you Dolly. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…
140
6
793
33,772
Jeromie Ballreich retweeted
What a rotten deal we made with Iran. We get nothing (except laughter at our stupidity). They get everything, including delay and big cash!
1,369
12,856
2,373
33,613
Jeromie Ballreich retweeted
Repatha’s withdrawal from Denmark is best understood as an early signal of the impact of Most Favored Nation drug pricing proposals in the US. When low-price foreign markets become linked to large U.S. markets, access disruptions are a predictable risk. | Forefront Nathan Jibat and @jeromie_b | @JohnsHopkins, @JohnsHopkinsSPH healthaffairs.org/content/fo…
1
1
2
470
Jeromie Ballreich retweeted
In their new #Crossroads article, @jeromie_b, @MichelleM_Mello, @MarissaReitsma, @SoyeonKang_PhD, @Angela_HSR, @jlevy2, @dr_msocal, Antonio Trujillo, and Gerard Anderson of @JohnsHopkinsSPH, @Stanford, and @Georgetown discuss how, for many ideas in President Trump’s two executive orders on prescription drug pricing, a large evidence base can assist federal officials in translating promising broad ideas into specific policies that are likely to deliver cost savings to US patients and programs. healthaffairs.org/content/fo…
2
2
5
1,231
Jeromie Ballreich retweeted
Researchers: need a pick-me-up? Check out the @Stata package MOTIVATE; it gives you motivational quotes to inspire you while coding. And while you're at it, check out the DEMOTIVATE package too. :)
5
29
4
196
17,601
Jeromie Ballreich retweeted
Happy to represent @JHSPH_CMAP @BSPH_HPM @JohnsHopkinsSPH @JohnsHopkins at the @scicoalition breakfast on the science of mental health and addiction at the US Senate this morning!
Join us on April 2 for The Science of: Addiction & Mental Health! Hear from leading research institutions & special guest @ESPN's @LaurenSisler on science-driven solutions for mental health and addiction. RSVP now: bit.ly/4iKmdh8
3
11
765
Jeromie Ballreich retweeted
Fact check: True This loophole encourages companies to move production and profits offshore even when selling to American consumers at the expense of domestic firms and workers. Closing it would create American jobs and raise $70 billion over 10 years. Here's how it works: Companies transfer IP created in the US to a foreign sub in a tax haven. This foreign affiliate uses the IP when manufacturing goods overseas that are then sold back into the US market. In effect, the IP’s value has “round-tripped” from the US to another country and then returned to the US as revenue from sales, avoiding taxes. This strategy is prevalent in sectors that combine complex manufacturing chains with outsized profit-making opportunity in the US — such as the pharma industry. The TCJA closed some, but not all, of this incentive. It must be fixed in the TCJA extension.
9
57
2
279
49,010
Jeromie Ballreich retweeted
Great example of confounding that affects retrospective studies. This one seems rather obvious, both low-birth weight and/or prematurity should have accounted for in some way.
A famous study found that Black babies have higher survival rates if attended by Black doctors than White doctors. But a re-analysis of the data shows the effect disappears after accounting for the fact that low birth weight babies more often see White doctors. [Link below.]
2
3
374
Is great to see this viewpoint in press. Unfortunately, the potential for CGT Access Model is in jeopardy with recent EOs. Ultimately, patients will lose out. @dr_msocal
Viewpoint: The Cell and Gene Therapy (CGT) Access Model has the potential to increase access to transformative therapies and set precedent for the use of outcomes-based agreement with future CGTs. ja.ma/4gAF0tO @jeromie_b
2
115
Jeromie Ballreich retweeted
This decision is misguided on multiple levels. First, $4 billion a year is a trivial amount for the wealthiest country in history—especially when compared to the cost of weakening one of its greatest assets: its research institutions. Second, the damage this will inflict on American research is enormous. Indirect costs support the infrastructure that enables cutting-edge discoveries, from lab facilities to compliance and administration. Slashing these funds will demoralize researchers, reduce institutional capacity, and drive talent elsewhere. In the long run, this weakens a fundamental pillar of U.S. strength—scientific leadership. Far from promoting efficiency, this move is penny-wise and pound-foolish, jeopardizing the very innovation that fuels economic growth, public health, and national security.
Last year, $9B of the $35B that the National Institutes of Health (NIH) granted for research was used for administrative overhead, what is known as “indirect costs.” Today, NIH lowered the maximum indirect cost rate research institutions can charge the government to 15%, above what many major foundations allow and much lower than the 60%+ that some institutions charge the government today. This change will save more than $4B a year effective immediately.
14
17
1
113
8,133
Jeromie Ballreich retweeted
"biggest, baddest, meanest guy"
By going after USAID the very first week, the White House has done what they say to do in prison: find the biggest, baddest meanest guy on your cell block, and sock him square in the jaw on Day 1.
1,138
2,913
125
46,316
2,040,953
Jeromie Ballreich retweeted
More on tomorrow’s conference . The panels will be 🔥
Meet the panelists for @JohnsHopkinsSPH's International Conference on Drug Pricing and Affordability: Panel 1 Diego Ocampo from @GrupoNeolpharma @profyadav from Council of Foreign Relations Katherine .E. Bliss from @CSISHealth (See more in replies.)
2
2
419
Jeromie Ballreich retweeted
Happening tomorrow - international conference on drug pricing and affordability . It will be an interesting discussion ! All-virtual format and free to register . Join us at tinyurl.com/DrugPricingConfe…
The International Conference on Drug Pricing and Affordability is a virtual conference with expert panelists on out of pocket spending for drugs; health technology; assessment and drug shortages; and the global supply chain. Register for this event: tinyurl.com/DrugPricingConfe…
1
2
239
Jeromie Ballreich retweeted
📢📢Call for Submissions📢📢 Check out Value & Outcomes Spotlight editorial themes for 2025! Go to ow.ly/E8HK50USMt6 to see the 2025 themes, learn more, and submit your manuscript today.
2
3
235
Jeromie Ballreich retweeted
Meet the panelists for @JohnsHopkinsSPH's International Conference on Drug Pricing and Affordability: Panel 1 Diego Ocampo from @GrupoNeolpharma @profyadav from Council of Foreign Relations Katherine .E. Bliss from @CSISHealth (See more in replies.)
The International Conference on Drug Pricing and Affordability is a virtual conference with expert panelists on out of pocket spending for drugs; health technology; assessment and drug shortages; and the global supply chain. Register for this event: tinyurl.com/DrugPricingConfe…
1
7
1
9
1,186
Jeromie Ballreich retweeted
The International Conference on Drug Pricing and Affordability is a virtual conference with expert panelists on out of pocket spending for drugs; health technology; assessment and drug shortages; and the global supply chain. Register for this event: tinyurl.com/DrugPricingConfe…
1
2
4
1,274
Jeromie Ballreich retweeted
Disappointed to see the new Trump EO that killed a promising idea on how to balance getting medicines to market faster with need to ensure those drugs are safe and effective. Today, drugmakers that get accelerated approval based on preliminary evidence are supposed to continue more rigorous clinical trials. But the incentive is wrong. The drugmaker gets to start selling the drug at full price. Thus there's no upside to a clinical trial, only downside. So drugmakers drag their feet on the trial, if it's even ever completed. CMS has the power to withdraw the drug if the trial isn't completed in a timely manner but that's too hard politically and rarely done. The proposal was to pay less for drugs that got accelerated approval until the confirmatory trial was finished. That would allow the drugs to get to market quickly but also create incentive for the drugmaker to complete the trial in a timely fashion. Getting drugs that don't work or are not safe to market earlier is not success. We need to balance time and evidence. This idea would have done so.
8
39
1
189
27,335
Jeromie Ballreich retweeted
Round 2 of drug price negotiations is up - and the GLP-1s ARE included
18
4
60
19,407
Jeromie Ballreich retweeted
Viewpoint: The Cell and Gene Therapy (CGT) Access Model has the potential to increase access to transformative therapies and set precedent for the use of outcomes-based agreement with future CGTs. ja.ma/3ZD2jgb @jeromie_b
1
1
743